Neurocrine Biosciences
NBIX
NBIX
483 hedge funds and large institutions have $9.2B invested in Neurocrine Biosciences in 2023 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 198 increasing their positions, 163 reducing their positions, and 86 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
34% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 86
42% less call options, than puts
Call options by funds: $17.5M | Put options by funds: $30.2M
Holders
483
Holding in Top 10
7
Calls
$17.5M
Puts
$30.2M
Top Buyers
| 1 | +$84.9M | |
| 2 | +$77.6M | |
| 3 | +$70M | |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$37.2M |
| 5 |
Primecap Management
Pasadena,
California
|
+$37.1M |
Top Sellers
| 1 | -$97.6M | |
| 2 | -$86.1M | |
| 3 | -$82.6M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$76.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$42.6M |